Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

924 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells.
Dyshlovoy SA, Kaune M, Hauschild J, Kriegs M, Hoffer K, Busenbender T, Smirnova PA, Zhidkov ME, Poverennaya EV, Oh-Hohenhorst SJ, Spirin PV, Prassolov VS, Tilki D, Bokemeyer C, Graefen M, von Amsberg G. Dyshlovoy SA, et al. Among authors: graefen m. Mar Drugs. 2020 Dec 1;18(12):609. doi: 10.3390/md18120609. Mar Drugs. 2020. PMID: 33271756 Free PMC article.
Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T. Minner S, et al. Among authors: graefen m. Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179235
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T. Minner S, et al. Among authors: graefen m. Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791629
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.
Hennigs JK, Müller J, Adam M, Spin JM, Riedel E, Graefen M, Bokemeyer C, Sauter G, Huland H, Schlomm T, Minner S. Hennigs JK, et al. Among authors: graefen m. PLoS One. 2014 Jul 10;9(7):e100469. doi: 10.1371/journal.pone.0100469. eCollection 2014. PLoS One. 2014. PMID: 25010045 Free PMC article.
Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy.
Schiffmann J, Lesmana H, Tennstedt P, Beyer B, Boehm K, Platz V, Tilki D, Salomon G, Petersen C, Krüll A, Graefen M, Schwarz R. Schiffmann J, et al. Among authors: graefen m. Strahlenther Onkol. 2015 Apr;191(4):330-7. doi: 10.1007/s00066-014-0794-y. Epub 2014 Dec 4. Strahlenther Onkol. 2015. PMID: 25471276 Clinical Trial.
924 results